Market research
WAVE.V Waverley Pharma Inc
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 540K
- P/E ratio
- 0.0
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 1.22
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA94357L1058
- Market cap
- 540K
- P/E ratio
- 0.0
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 1.22
About
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the WAVE.V discussion.
5 years, 5 months ago
Waverley Pharma Inc is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Waverley Pharma Inc's total revenue rose by 33.7% to $353K since the same quarter in the previous year.
Its net income has increased by 100.2% to $989 since the same quarter in the previous year.
Finally, its free cash flow grew by 129.3% to $179K since the same quarter in the previous year.
Based on the above factors, Waverley Pharma Inc gets an overall score of 4/5.